Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier

[1]  B. Trock,et al.  Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier , 2020, Prostate Cancer and Prostatic Diseases.

[2]  M. Loda,et al.  Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. , 2019, European urology.

[3]  J. Eastham,et al.  LBA-12 CALGB 90203 (ALLIANCE): RADICAL PROSTATECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOHORMONAL THERAPY IN MEN WITH CLINICALLY LOCALIZED, HIGH RISK PROSTATE CANCER , 2019, Journal of Urology.

[4]  R. Hannan,et al.  Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Steven L. Chang,et al.  Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  F. Saad,et al.  Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial. , 2019, Journal of Clinical Oncology.

[7]  A. D'Amico,et al.  Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015 , 2019, JAMA.

[8]  T. H. van der Kwast,et al.  Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. , 2019, International journal of radiation oncology, biology, physics.

[9]  Misop Han,et al.  Outcomes of very high‐risk prostate cancer after radical prostatectomy: Validation study from 3 centers , 2018, Cancer.

[10]  M. Cooperberg,et al.  The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. , 2018, European urology.

[11]  J. Bahary,et al.  Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. , 2018, European urology.

[12]  Mohammad Hossein Khosravi,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 , 2018, JAMA oncology.

[13]  M. Cooperberg,et al.  Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. , 2018, European urology.

[14]  P. Carroll,et al.  Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  B. Trock,et al.  Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. , 2017, European urology.

[16]  M. Parmar,et al.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy , 2017, The New England journal of medicine.

[17]  B. Trock,et al.  Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Carroll,et al.  PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. , 2016, European urology focus.

[19]  M. Cooperberg,et al.  Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. , 2016, The Journal of molecular diagnostics : JMD.

[20]  Jianbo Li,et al.  Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. , 2016, Urology.

[21]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[22]  M. Cooperberg,et al.  Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.

[23]  B. Escudier,et al.  Who dies from prostate cancer? , 2014, Prostate Cancer and Prostatic Disease.

[24]  C. Kane,et al.  Robotic-assisted simple prostatectomy: a systematic review and report of a single institution case series , 2013, Prostate Cancer and Prostatic Disease.

[25]  Mark W. Ball,et al.  Very high risk localized prostate cancer: definition and outcomes , 2013, Prostate Cancer and Prostatic Disease.

[26]  Anirban P. Mitra,et al.  Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy , 2013, PloS one.

[27]  A. Partin,et al.  Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. , 2012, Urology.

[28]  P. Scardino,et al.  Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. , 2008, European urology.

[29]  M. Cooperberg,et al.  Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). , 2003, The Journal of urology.

[30]  J. Epstein,et al.  Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group , 2018, JAMA Oncology.

[31]  B. Trock,et al.  Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. , 2016, European urology.

[32]  A. D'Amico,et al.  NCCN clinical practice guidelines in oncology: prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[33]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.